Non-GLP sample analysis for ocular biodistribution studies

Traditional bioanalytical service providers are geared toward analyzing large sets of samples under various regulatory guidelines, such as large nonclinical and clinical studies, which are heavily regulated. This puts a heavy burden on these service providers, creating long lead times, resource constraints and lack of flexibility. Currently, many bioanalytical laboratories report lead times of six to nine months to begin development work. These limited bioanalytical options are causing extensive delays in overall drug development affecting the finances of sponsors. 

PK, PD and immunogenicity assays to support clinical trials – building the bigger picture

Understanding how a body processes a therapy and a therapy’s effect on the body is a critical step for understanding safety and efficacy to support clinical trials. But the process of characterization differs between small-molecule therapies and biotherapeutics. 

Welcome to the digital future of pathology

Imagine getting a phone call in the middle of your study from a scientist who is seeing something completely unexpected in your study results. You need to make a decision on how to move forward and you need to do it quickly. You don’t have time to wait for a shipment of glass pathology slides. Now imagine being able to not only listen to them describe what they see, but actually see it for yourself and review it with them live.

Balancing precision and recall in the pharmacovigilance (PV) literature monitoring

In pattern recognition, information retrieval and classification (machine learning), precision and recall are performance metrics that apply to data retrieved from a collection, corpus or sample space.

Labcorp DCT representation at ARCS, Medidata NEXT, DIA and more – July 2022

Welcome to the July 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. This month, we are going to review our recent presence at several important industry events and provide you with links to a new case study and a just-released video about our snapClinical® technology platform.

More than a partner: How Labcorp Central Laboratories managed the 65-day Shanghai lockdown

With five global central laboratories, Labcorp understands the value of around-the-clock support to advance clinical trial testing, but the recent 65-day lockdown at their Shanghai facilities gave new meaning to “around the clock.”

Cell and Gene Therapy Answers: Bioanalytical support for cell and gene therapy

We recently spoke with Daniel Sikkema, executive director of global immunochemistry at Labcorp drug development, regarding bioanalytical support for cell and gene therapy modalities. He shared some of the current challenges in cell and gene therapy, how the Labcorp Bioanalytical Services group contributes to the development of cell and gene therapy and the path forward as new treatments continue to be developed.

Labcorp to open new kit production innovation base in Suzhou, China

In late July, Labcorp joined the signing ceremony of its kit production innovation base project in Suzhou New District, China. The event was held and organized by the Suzhou New District government and saw attendance from city leadership officials, including Deputy Mayor of Suzhou city, Mr. Xiaodong Tang.

snapClinical® team launches eSource module to revolutionize at-home care for Labcorp Drug Development Mobile Clinical Services

Labcorp Drug Development Mobile Clinical Services (MCS) team has now completed the first global visit utilizing the eSource module of the proprietary Labcorp DCT platform, snapClinical.  This module represents a cross-functional effort to develop a solution digitizing the at-home trial service workflow. Namely, the module seeks to accelerate requesting and assigning country-level resources, facilitate visit completion with a native application to accelerate data availability and ultimately decrease manual processes when leveraging at-home clinical services such as nursing and biological specimen collection. By leveraging an all-in-one DCT platform combining eSource with eConsent, ePRO and telemedicine, Labcorp DCTs are able to provide solutions tailored to the needs of patient populations; investigators and sites are also able to access and review data from a single access point. This new module embodies the “built-in, not bolted-on” approach that Labcorp DCTs have pioneered.

European Society for Medical Oncology: Understanding barriers to accessible cancer care

The European Society for Medical Oncology (ESMO) recently held its first in-person congress since the COVID-19 pandemic. The conference, held in Paris, brought together more than 22,000 attendees to share and discuss the latest evidence and issues in cancer care. A common thread running through the congress program was ESMO’s Vision 2025—a commitment of “shared determination to secure the best possible outcomes for patients.” Vision 2025 outlines a three-tiered approach to achieving this: